JP2022538237A5 - - Google Patents
Info
- Publication number
- JP2022538237A5 JP2022538237A5 JP2021576635A JP2021576635A JP2022538237A5 JP 2022538237 A5 JP2022538237 A5 JP 2022538237A5 JP 2021576635 A JP2021576635 A JP 2021576635A JP 2021576635 A JP2021576635 A JP 2021576635A JP 2022538237 A5 JP2022538237 A5 JP 2022538237A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- subject
- pharmaceutical composition
- dose
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025087586A JP2025138634A (ja) | 2019-06-24 | 2025-05-27 | B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962865381P | 2019-06-24 | 2019-06-24 | |
| US62/865,381 | 2019-06-24 | ||
| US201962940589P | 2019-11-26 | 2019-11-26 | |
| US62/940,589 | 2019-11-26 | ||
| US202062967401P | 2020-01-29 | 2020-01-29 | |
| US62/967,401 | 2020-01-29 | ||
| US202063034106P | 2020-06-03 | 2020-06-03 | |
| US63/034,106 | 2020-06-03 | ||
| PCT/IB2020/055872 WO2020261093A1 (en) | 2019-06-24 | 2020-06-22 | Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025087586A Division JP2025138634A (ja) | 2019-06-24 | 2025-05-27 | B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022538237A JP2022538237A (ja) | 2022-09-01 |
| JP2022538237A5 true JP2022538237A5 (cg-RX-API-DMAC7.html) | 2023-06-27 |
Family
ID=71738213
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576635A Withdrawn JP2022538237A (ja) | 2019-06-24 | 2020-06-22 | B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
| JP2025087586A Pending JP2025138634A (ja) | 2019-06-24 | 2025-05-27 | B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025087586A Pending JP2025138634A (ja) | 2019-06-24 | 2025-05-27 | B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220332821A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3986569A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022538237A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220024729A (cg-RX-API-DMAC7.html) |
| CN (2) | CN114286828A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020307471A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3144324A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL289187A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202115114A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020261093A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015292744C1 (en) | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| KR102530742B1 (ko) | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | 단일 도메인 혈청 알부민 결합 단백질 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CA3078969A1 (en) | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN119306844A (zh) | 2018-09-25 | 2025-01-14 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| AU2020279224B2 (en) | 2019-05-21 | 2024-12-05 | Novartis Ag | Trispecific binding molecules against BCMA and uses thereof |
| HUE068401T2 (hu) | 2019-11-11 | 2024-12-28 | Amgen Res Munich Gmbh | A BCMA elleni hatóanyagok adagolási rendje |
| CN116249548A (zh) | 2020-05-11 | 2023-06-09 | 詹森生物科技公司 | 用于治疗多发性骨髓瘤的方法 |
| JP2023524854A (ja) * | 2020-05-13 | 2023-06-13 | ファイザー・インク | がんを処置するための方法、治療、および使用 |
| KR20230069181A (ko) * | 2020-09-14 | 2023-05-18 | 화이자 인코포레이티드 | 암 치료를 위한 방법, 요법 및 용도 |
| JP2024504454A (ja) * | 2021-01-29 | 2024-01-31 | 上▲海▼翰森生物医▲薬▼科技有限公司 | 抗体-薬物コンジュゲート及びその医学的使用 |
| CN115521381B (zh) * | 2021-06-24 | 2024-10-29 | 益科思特(北京)医药科技发展有限公司 | 结合bcma和cd3的双特异性抗体及其制备方法与应用 |
| TW202325743A (zh) * | 2021-07-14 | 2023-07-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合cd38、bcma和cd3的抗原結合分子及其醫藥用途 |
| CN113908395B (zh) * | 2021-10-13 | 2024-05-17 | 科悦医疗(苏州)有限公司 | 一种促醒仪 |
| EP4426437A4 (en) * | 2021-11-03 | 2025-09-17 | Janssen Biotech Inc | METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES |
| KR20260057078A (ko) * | 2023-08-18 | 2026-04-27 | 브리스톨-마이어스 스큅 컴퍼니 | Bcma 및 cd3에 결합하는 항체를 포함하는 조성물 및 치료 방법 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JPH11507538A (ja) | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
| US7468365B2 (en) | 2000-11-17 | 2008-12-23 | Eli Lilly And Company | Lactam compound |
| GB0120347D0 (en) | 2001-08-21 | 2001-10-17 | Merck Sharp & Dohme | Therapeutic agents |
| BRPI0413533A (pt) | 2003-09-09 | 2006-10-10 | Hoffmann La Roche | derivados de malonamida que bloqueiam a atividade de gama-secretase |
| EP1680406A1 (en) | 2003-10-29 | 2006-07-19 | Elan Pharmaceuticals, Inc. | N-substituted benzene sulfonamides |
| EP1702626B1 (en) | 2003-12-30 | 2011-11-30 | Kowa Company, Ltd. | Screening method for gamma-secretase inhibitors |
| AP2379A (en) | 2004-03-23 | 2012-03-08 | Pfizer Prod Inc | Imidazole compounds for the treatment of neurodegenerative disorders. |
| WO2007019232A2 (en) * | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
| CA2641013A1 (en) | 2006-02-17 | 2007-08-30 | Wyeth | Methods for preparing sulfonamide substituted alcohols and intermediates thereof |
| EP2011513B1 (en) | 2006-04-25 | 2016-10-19 | The University of Tokyo | Therapeutic agents for alzheimer's disease and cancer |
| US20110257163A1 (en) | 2007-08-07 | 2011-10-20 | Schering Corporation | Gamma secretase modulators |
| KR101136260B1 (ko) | 2007-08-14 | 2012-04-19 | 일라이 릴리 앤드 캄파니 | 감마-세크레타제 억제제로서의 아제핀 유도체 |
| US8084477B2 (en) | 2007-10-31 | 2011-12-27 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯二氮呯酮化合物 |
| US9096582B2 (en) | 2011-10-31 | 2015-08-04 | Merck Sharp & Dohme Corp | Gamma secretase modulators |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
| EP2925313A4 (en) | 2012-11-29 | 2016-05-11 | Merck Sharp & Dohme | SPIROCYCLIC SULPHONES AS GAMMA SECRETASE INHIBITORS |
| UY36401A (es) * | 2014-11-14 | 2016-06-30 | Novartis Ag | Conjugados anticuerpos-fármacos |
| JP6696982B2 (ja) * | 2014-11-26 | 2020-05-20 | ゼンコー・インコーポレイテッドXencor、 Inc. | Cd3および腫瘍抗原に結合するヘテロ二量体抗体 |
| HK1245171A1 (zh) * | 2014-11-26 | 2018-08-24 | Xencor, Inc. | 结合cd3和cd38的异二聚体抗体 |
| HUE057285T2 (hu) | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| EP3324965A4 (en) | 2015-07-24 | 2019-07-03 | Oncotracker, Inc. | Gamma secretase modulators for the treatment of immune system dysfunction |
| CN109310755A (zh) * | 2016-02-02 | 2019-02-05 | 卡德门企业有限公司 | Pd-l1和kdr的双特异性结合蛋白 |
| US11124577B2 (en) * | 2016-11-02 | 2021-09-21 | Engmab Sàrl | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| PE20210320A1 (es) * | 2018-06-01 | 2021-02-16 | Novartis Ag | Moleculas de union contra bcma y usos de las mismas |
-
2020
- 2020-06-22 AU AU2020307471A patent/AU2020307471A1/en not_active Abandoned
- 2020-06-22 US US17/620,987 patent/US20220332821A1/en active Pending
- 2020-06-22 CN CN202080059452.0A patent/CN114286828A/zh active Pending
- 2020-06-22 CA CA3144324A patent/CA3144324A1/en active Pending
- 2020-06-22 TW TW109121083A patent/TW202115114A/zh unknown
- 2020-06-22 JP JP2021576635A patent/JP2022538237A/ja not_active Withdrawn
- 2020-06-22 KR KR1020227001880A patent/KR20220024729A/ko not_active Withdrawn
- 2020-06-22 CN CN202411465492.1A patent/CN119679936A/zh active Pending
- 2020-06-22 EP EP20743802.9A patent/EP3986569A1/en active Pending
- 2020-06-22 WO PCT/IB2020/055872 patent/WO2020261093A1/en not_active Ceased
-
2021
- 2021-12-20 IL IL289187A patent/IL289187A/en unknown
-
2025
- 2025-05-27 JP JP2025087586A patent/JP2025138634A/ja active Pending